AASLD Interview | Professor Vincent Wai-Sun Wong: Global Differences and New Advances in the Diagnosis and Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

AASLD Interview | Professor Vincent Wai-Sun Wong: Global Differences and New Advances in the Diagnosis and Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

In his research, Vincent Wai-Sun Wong performs multidisciplinary study on Steatohepatitis and Fatty liver. Fatty liver is frequently linked to Disease in his study. His studies link Steatohepatitis with Disease. His Gastroenterology study frequently links to adjacent areas such as Transient elastography. Transient elastography and Biopsy are commonly linked in his work. He integrates Biopsy and Fibrosis in his studies. Vincent Wai-Sun Wong conducts interdisciplinary study in the fields of Fibrosis and Inflammation through his research. His work blends Inflammation and Liver disease studies together. In his study, he carries out multidisciplinary Liver disease and Cirrhosis research.
Interview with AASLD President Norah Terrault: A Resurgence of Vitality in the Field of Liver Disease, Highlights Galore at This Year’s Conference

Interview with AASLD President Norah Terrault: A Resurgence of Vitality in the Field of Liver Disease, Highlights Galore at This Year’s Conference

Dr. Norah Terrault is Professor of Medicine and Chief of Gastroenterology and Liver Diseases and Neil Kaplowitz Endowed Chair in Liver Diseases Research. She received her MD from the University of Alberta and completed fellowships in Internal Medicine and Gastroenterology at the University of Toronto and a Masters in Public Health at the University of California at Berkeley. Dr. Terrault has focused her clinical and research activities on viral hepatitis and steatotic liver disease (metabolic and alcohol-associated), especially in special populations including those with cirrhosis and those with transplants. In addition to multiple clinical trials related to preventing and treating chronic hepatitis viral hepatitis and metabolic steatotic liver disease, Dr. Terrault has been PI on multiple NIH-funded studies, including the current NIDDK-supported Liver Cirrhosis Network and nonalcoholic steatohepatitis clinical research network (NASH CRN). She has authored more than 450 peer-reviewed manuscripts, editorials, and invited reviews as well as co-authoring US national guidelines for treatment of chronic hepatitis B and C and alcohol-associated liver disease. She is past associate editor for Hepatology and deputy editor for Liver Transplantation and co-edited Zakim and Boyer’s textbook in hepatology. Dr. Terrault is currently serving as the president of the American Association for the Study of Liver Diseases (AASLD). She is the founder of USC Project ECHO, a multifaceted program to train and support primary care physicians in California to care for patients with viral hepatitis. She has a long history of mentoring fellows and junior faculty in clinical research and is passionate about creating research support and opportunities for the next generation of GI/Hepatology investigators.
AASLD Hot Topic | Dr. Zhihong Liu of Southern Hospital: Hepatitis B Expanded Treatment, Simplified Treatment, and Progress in Functional Cure Drugs

AASLD Hot Topic | Dr. Zhihong Liu of Southern Hospital: Hepatitis B Expanded Treatment, Simplified Treatment, and Progress in Functional Cure Drugs

The AASLD (American Association for the Study of Liver Diseases) 2023 conference was held in Boston, USA, from November 10th to 14th, marking a significant event in the field of hepatology. Hepatology Digest's reporting team was fortunate to invite Dr. Zhihong Liu from the Department of Infectious Diseases and Hepatology at Southern Hospital of Southern Medical University to share insights from the AASLD and discuss the work presented by his team at the conference, along with their learning experiences.
Prediction of HVPG Score for TACE Treatment Outcome in Liver Cancer Based on CT Deep Learning Model

Prediction of HVPG Score for TACE Treatment Outcome in Liver Cancer Based on CT Deep Learning Model

From November 10 to 14, 2023, the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2023) was held in Boston, USA. The CHANCE-CHESS series research results, led by Academician Gaojun Teng, President of the Interventional Physicians Branch of the Chinese Medical Association, Director of the Affiliated Zhongda Hospital of Southeast University, and founder of CHANCE, as well as Professor Xiaolong Qi, Assistant Director of the Affiliated Zhongda Hospital of Southeast University and head of CHESS, were orally presented at the conference.
AASLD Interview | Dr. Jian Wu’s Research Group at Fudan University Shanghai Medical College Shares Highlights and Insights from AASLD 2023

AASLD Interview | Dr. Jian Wu’s Research Group at Fudan University Shanghai Medical College Shares Highlights and Insights from AASLD 2023

Since 1997, Professor Jian Wu's research group at Fudan University Shanghai Medical College has been actively participating in the annual meeting of the American Association for the Study of Liver Diseases (AASLD 2023). This year, the research group has had four abstracts selected for poster presentations and one abstract chosen for an oral presentation in a thematic session. The selected abstracts primarily focus on three main topics: the molecular basis of the Hedgehog signaling pathway in hepatocellular carcinoma; the molecular mechanisms of the JCAD protein in liver fibrosis and regeneration; and the mechanisms by which gut microbiota-derived metabolites promote the progression of chronic liver disease. "Hepatology Digest" had the privilege of inviting Dr. Jian Wu to the conference to discuss the research findings and their significance, share insights and advice on scientific research, and talk about the topics and experiences that caught his interest during the conference. The interview video and summaries of the five research presentations are provided below.
Multiple Studies on Antiviral Treatment for Chronic Hepatitis B Selected for Conference Exchange, with a Focus on the Stability of Decompensation

Multiple Studies on Antiviral Treatment for Chronic Hepatitis B Selected for Conference Exchange, with a Focus on the Stability of Decompensation

From November 10th to 14th, 2023, the American Association for the Study of Liver Diseases (AASLD) Annual Meeting was grandly held in Boston, USA. In this event, Dr. Wen Xie's team from Beijing Ditan Hospital, Capital Medical University, presented several notable research findings. One of them is a study on the stability of decompensation in patients with chronic hepatitis B and liver cirrhosis treated with entecavir (ETV) [1], which received the Outstanding Abstract Award at the conference. Hepatology Digest reports on these research findings as follows.
Dr. Jing Zhang: Team’s 7 Achievements in the Fields of Fatty Liver, Cirrhosis, and Hepatitis C, Research Insights, and Future Directions

Dr. Jing Zhang: Team’s 7 Achievements in the Fields of Fatty Liver, Cirrhosis, and Hepatitis C, Research Insights, and Future Directions

From November 10th to 14th, 2023, the American Association for the Study of Liver Diseases (AASLD) Annual Meeting 2023 was held in Boston, USA. Professor Jing Zhang and her team from Beijing Youan Hospital, Capital Medical University, have long focused on scientific research in chronic liver diseases. Seven research findings from the team were included in the conference and presented in poster form, covering non-alcoholic fatty liver disease (NAFLD) [1-3], cirrhosis [4-5], and hepatitis C [6-7]. "Hepatology Digest" had the privilege of inviting Professor Jing Zhang for an interview at the conference to introduce the research findings, share insights into clinical research, and discuss topics of interest and future research directions. The interview video and some research content are shared below.
AASLD Voice of China | Dr. Hong Tang’s Team: Multiple Research Achievements in the Fields of Hepatitis B, Hepatitis C, and Non-Alcoholic Fatty Liver D

AASLD Voice of China | Dr. Hong Tang’s Team: Multiple Research Achievements in the Fields of Hepatitis B, Hepatitis C, and Non-Alcoholic Fatty Liver D

From November 10th to 14th, 2023, the American Association for the Study of Liver Diseases Annual Meeting (AASLD2023) was held in Boston, USA. Professor Hong Tang's team from West China Hospital of Sichuan University presented multiple research studies in the fields of hepatitis B, hepatitis C, and non-alcoholic fatty liver disease (NAFLD) at the conference. The research was included in the conference proceedings and presented in the form of posters. Congratulations to the team! Hepatology Digest reports on these research findings, and the relevant content is summarized below.
AASLD 2023丨Landmark Chinese Study on NASH Treatment Presented at AASLD

AASLD 2023丨Landmark Chinese Study on NASH Treatment Presented at AASLD

On November 11, 2023, at the American Association for the Study of Liver Diseases annual meeting (AASLD 2023), the results of China's first international registered randomized controlled trial (RCT) evaluating therapeutic efficacy through liver histology, known as the VENS study, were showcased in poster format. This presentation garnered significant attention and discussions from international experts in liver diseases. The conference brought together leading global experts in clinical hepatology, liver transplantation, and hepatobiliary surgery to advance clinical research and practices, providing optimal treatment guidance for liver and biliary disease patients.
Focusing on Hepatitis B, New Developments in the “Oasis” Project and Exploration of TAF’s Immune Modulation Effects

Focusing on Hepatitis B, New Developments in the “Oasis” Project and Exploration of TAF’s Immune Modulation Effects

The annual highlight in the field of hepatology, the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting, is currently taking place in Boston, USA. Two research achievements related to the treatment and management of hepatitis B by Dr. Wenhong Zhang and Dr. Jiming Zhang 's team from Huashan Hospital, affiliated with Fudan University, have been included in the conference. One is a phase analysis of the Oasis Project, a study aimed at reducing the occurrence of liver cancer in Chinese hepatitis B patients, revealing the safety and benefits of interferon application in specific populations. The other explores the immune modulation effects of tenofovir alafenamide (TAF) treatment and predictive indicators of efficacy. "Hepatology Digest" hereby reports on these findings.